ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1431

Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center

Ekemini Ogbu1,2, Shanmuganathan Chandrakasan1,2, Sunita Park1,2 and Sampath Prahalad1,2, 1Pediatrics, Emory University, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fever, Lymph node, race/ethnicity and sex bias

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Kikuchi-Fujimoto Disease (KFD) is often described as a benign self-limited disease. However, there is a risk of recurrence. It is most common in adult Asian females but has been reported in other races and in children. Prior studies have noted differences between pediatric and adult cases and suggest that male children are more affected than female children. However, these were mostly Asian studies raising the question of racial and sex differences of this disease in other populations. In particular, studies from North America is lacking. As we have one of the largest, diverse centers in the US, our objective was to describe our cohort of pediatric patients with KFD and to examine racial and gender differences in clinical and laboratory parameters.

Methods:

We conducted a retrospective study of patients diagnosed at our center from January 1, 2007 to January 1, 2017. Using natural language selection, patients with biopsy-proven KFD were identified from our institutional pathology database and included in our study. We extracted corresponding clinical and laboratory data from our electronic medical records. We excluded patients older than 18 years at the time of diagnoses and patients with a concurrent or pre-existing diagnosis of systemic lupus erythematosus. IRB approval of the study protocol with waiver of informed consent was obtained from our institution.

Results:

We identified 23 patients with KFD who met our inclusion and exclusion criteria as shown in table 1 with racial and sex comparisons in table 2. The majority of our patients were Black (74%). Female to male ratio was 1.3:1. Mean age for males was significantly lower than for females. Bilateral cervical lymphadenopathy, fever, fatigue and elevated lactose dehydrogenase were common. There were more males with severe KFD, consisting of fever and weight loss, than females. The odds of having severe KFD in males was 12.831 times the odds in females (95% CI 1.694, 97.172 p-value 0.0135). Median follow-up period was 4 months. Four patients (17%) had a recurrence of disease during their follow-up. We found no significant difference in clinical or laboratory data in Black patients compared to other races.

Conclusion:

To the best of our knowledge, this is the largest pediatric study of KFD in the US. Our findings show a slight female predominance and higher recurrence rate relative to prior pediatric reports. This strengthens the need for longitudinal studies on patients with KFD to determine risk factors for recurrence.

Table 1: Descriptive Characteristics of Patients with Kikuchi- Fujimoto Disease

Characteristic

N (%) (n=23)

Missing = N

Demographics

Sex

Female

13 (56.52)

Male

10(43.48)

Race

Black or African American

17 (73.91)

Other

6 (26.09)

Ethnicity

Non-Hispanic or Latino

22 (95.65)

Hispanic or Latino

1 (4.35)

Age in years

13 (3.59)a

Clinical characteristics

Fever

19 (82.61)

Arthritis

1(4.35)

Headache

10 (45.45)

1

Arthralgia

5 (21.74)

Fatigue

18 (78.26)

Sore throat

5 (21.74)

Weight loss

10 (43.48)

Cervical lymphadenopathy

22 (95.65)

Bilateral

10 (43.48)

Left only

8 (34.78)

Right only

4 (17.39)

Deep lymphadenopathy

4 (19.05)

Hepatomegaly

1 (4.35)

Splenomegaly

3 (13.04)

Severe KFD (Fever and weight loss)

9 (39.13)

Laboratory characteristics

Positive ANA (≥ 1:80)

4 (66.67)

17

Anemia (hemoglobin ≤ 10g/dl)

6 (27.27)

1

Thrombocytopenia (<150000/uL)

4 (18.18)

1

Leukopenia (<3500/uL)

13 (59.09)

1

Lymphopenia (<1000/uL)

7 (30.43)

1

Neutropenia (<1500/uL)

10 (45.45)

1

Low albumin (<3.5g/dl)

9 (52.94)

6

Elevated Alanine Transaminase (>24U/L)

15 (75.00)

3

Elevated Aspartate Transaminase (>33U/L)

17 (85.00)

3

Elevated C-Reactive Protein (>1.0 mg/dl)

13 (72.22)

5

Elevated Erythrocyte Sedimentation Rate (>20mm/hr)

15 (65.22)

Elevated Ferritin (>67.4 ng/ml)

10 (100.00)

13

Elevated Lactate Dehydrogenase (>400 U/L)

15 (88.24)

6

Elevated Uric Acid (>5.4mg/dl)

1(5.26)

4

Outcome

Symptom onset to diagnosis in weeks

4 (3.00)b

Follow-up in months

4 (23.90)b

3

Received treatment

11 (50.00)

1

Recurrence

4 (17.39)

Abbreviations: ANA = Anti-nuclear antibody; KFD = Kikuchi-Fujimoto Disease.

a Mean (SD) b Median (IQR)

Table 2: Comparison of Patients with Kikuchi- Fujimoto Disease by Sex and Race

Female

Male

P-valuec

Black

Other race

P-valuec

N (%) (n=13)

N (%) (n=10)

N (%) (n=17)

N (%) (n=6)

Age in years a

15(2.24)

10(4.30)

0.05S

14(3.76)

15(4.00)

0.76

Female

9(52.94)

4(66.67)

0.66

Black

9(69.23)

8(80.00)

0.66

Clinical characteristics

Fever

10(76.92)

9(90.00)

0.60

14(82.35)

5(83.33)

1.00

Arthritis

1(7.69)

0(0.00)

1.00

1(5.88)

0(0.00)

1.00

Headache

6(50.00)

4(40.00)

0.69

6(37.50)

4(66.67)

0.35

Arthralgia

3(23.08)

2(20.00)

1.00

4(23.53)

1(16.67)

1.00

Fatigue

10(76.92)

8(80.00)

1.00

14(82.35)

4(66.67)

0.58

Sore throat

2(15.38)

3(30.00)

0.62

4(23.53)

1(16.67)

1.00

Weight loss

3(23.08)

7(70.00)

0.04S

6(35.29)

4(66.67)

0.34

Cervical lymphadenopathy

12(92.31)

10(100.00)

1.00

16(94.12)

6(100.00)

1.00

Bilateral

5(38.46)

5(50.00)

7(41.18)

3(50.00)

Left only

5(50.00)

3(30.00)

5(29.41)

3(50.00)

Right only

2(15.38)

2(20.00)

4(23.53)

0(0.00)

Deep lymphadenopathy

3(25.00)

1(11.11)

0.60

3(20.00)

1(16.67)

1.00

Hepatomegaly

0(0.00)

1(10.00)

0.43

1(5.88)

0(0.00)

1.00

Splenomegaly

0(0.00)

3(30.00)

0.07

2(11.76)

1(16.67)

1.00

Severe KFD (Fever and weight loss)

2(15.38)

7(70.00)

0.01S

5(29.41)

4(66.67)

0.16

Laboratory characteristics

Anemia (hemoglobin ≤ 10g/dl)

4(33.33)

2(20.00)

0.65

4(25.00)

2(33.33)

1.00

Thrombocytopenia (<150000/uL)

2(16.67)

2(20.00)

1.00

3(18.75)

1(16.67)

1.00

Leukopenia (<3500/uL)

6(50.00)

3(30.00)

0.42

9(56.25)

4(66.67)

1.00

Lymphopenia (<1000/uL)

5(38.46)

2(20.00)

0.41

6(35.29)

1(16.67)

0.62

Neutropenia (<1500/uL)

5(41.67)

5(50.00)

1.00

7(43.75)

3(50.00)

1.00

Low albumin (<3.5g/dl)

5(55.56)

4(50.00)

1.00

7(53.83)

2(40.00)

0.62

Elevated Alanine Transaminase (>24U/L)

8(72.73)

7(77.78)

1.00

11(73.33)

4(80.00)

1.00

Elevated Aspartate Transaminase (>33U/L)

9(81.82)

8(88.89)

1.00

13(86.67)

4(80.00)

1.00

Elevated C-Reactive Protein (>1.0 mg/dl)

Elevated Erythrocyte Sedimentation Rate (>20mm/hr)

10(76.92)

5(50.00)

0.22

10(58.82)

5(83.33)

0.37

Elevated Lactate Dehydrogenase (> 400U/L)

7 (87.50)

8(88.89)

1.00

12(92.31)

3(75.00)

0.43

Outcome

Symptom onset to diagnosis in weeksb

4(4.00)

4(2.00)

0.05S

4(1.00)

6(4.00)

0.16

Follow-up in monthsb

3(22.00)

6(25.88)

0.92

13(33.00)

4(4.00)

0.03S

Received treatment

7(58.33)

4(40.00)

0.67

7(43.75)

4(66.67)

0.64

Recurrence

2(15.38)

2(20.00)

1.00

4(23.53)

0(0.00)

0.54

Abbreviations: ANA = Anti-nuclear antibody; KFD = Kikuchi-Fujimoto Disease.

a Mean (SD) b Median (IQR) c Fishers exact test SStatistically significant with p-value <0.05.


Disclosure: E. Ogbu, None; S. Chandrakasan, None; S. Park, None; S. Prahalad, None.

To cite this abstract in AMA style:

Ogbu E, Chandrakasan S, Park S, Prahalad S. Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/kikuchi-fujimoto-disease-a-retrospective-analysis-of-23-pediatric-cases-from-a-us-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kikuchi-fujimoto-disease-a-retrospective-analysis-of-23-pediatric-cases-from-a-us-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology